Novartis Exceeds Expectations (cross-border guide)

Context

In a nutshell - Novartis had $14.4 billion in revenue in the second quarter of 2026. - Revenue growth was 3% in nominal terms and 1% at constant exchange rates. ## Key facts - Revenue: $14.4 billion - Revenue growth: 3% in nominal terms - Constant exchange rates: 1% - Core operating profit: $5.9 billion - Operating margin: 41.2% Novartis today announced its financial results for the second quarter of 2026. Revenue was $14.4 billion, up 3% in nominal terms and 1% at constant exchange rates. Basic operating profit was 5.9 billion, with an operating margin of 41.2%. The CEO of Novartis, said: "We are pleased with the results achieved in the second quarter, despite the global challenges. Our diversification strategy continues to bear fruit, with a 3% increase in turnover in nominal terms.” Turnover growth was mainly driven by the sale of cancer treatment drugs, which contributed 60% of total turnover. The Asia-Pacific market region recorded a growth of 10% compared to the same period of the previous year. Turnover growth was also influenced by the growth in demand for drugs for the treatment of Parkinson's disease, which registered an increase of 15% compared to the same period of the previous year. Novartis has The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced its intention to increase investment in the research and development of new drugs, with a 20% increase compared to 2025. The company also announced plans to increase investment in research

Operational details

Novartis' revenue growth exceeded experts' expectations. The Rhine pharmaceutical giant confirmed its annual targets, forecasting constant-currency revenue growth in the low end of the single-digit range and a decline in adjusted operating profit in the low end of the single-digit range. Price effects had a negative impact, while exchange rate effects had a positive effect.

Novartis achieved a turnover of CHF 49.2 billion, slightly exceeding the expectations of experts, who expected a turnover of CHF 48.8 billion. The pharmaceutical giant confirmed its annual targets, despite the negative effects of prices and research and development costs.

Novartis' turnover was affected by drug prices, which had a negative impact of 2.5% on turnover. However, the positive effects of foreign exchange helped to offset the loss of turnover due to prices, with a positive contribution of 1.8% to turnover.

Novartis also announced that its adjusted operating profit was down 6.2% from the previous year, due to research and development costs and expenses for research and development of new drugs. The pharmaceutical giant confirmed that it invested 12.5 billion Swiss francs in research and development of new drugs in 2022.

Novartis' revenue growth is

Useful tools to protect your net income

To reduce FX leakage, compare CHF-EUR exchange options and banks for cross-border workers.

Key points

Novartis Exceeds Expectations: A Detailed View The Swiss pharmaceutical company Novartis recently released its financial results for the first half of the current year, exceeding analysts' expectations. However, revenue growth at constant currencies is expected to be in the low end of the single-digit range, which could be affected by price effects on financial performance. Regarding the future outlook, Novartis has confirmed its annual targets. Constant currency revenue growth is expected in the low end of the single digit and adjusted operating profit decline in the low end of the single digit. It is important to note that price effects could have a negative impact on the financial result. The company also announced that it had reached an agreement with the city of Basel for the construction of a new research and development centre. This project, which involves an investment of 200 million Swiss francs, is expected to be completed by 2025 and is expected to create around 100 new jobs. In addition, Novartis confirmed that it is working to develop new therapies for rare diseases, with a particular focus on finding new solutions for the treatment of multiple sclerosis. This is an area in which the company has already shown itself to be a leader, thanks to its basic therapy for multiple sclerosis, which has been approved in The company also announced that it has reached an agreement with the Swiss federal government for the creation of an investment fund for the research and development of new technologies. This fund, which provides for an investment of 500 million Swiss francs, is expected to be completed by 2028 and is expected to create around 200 new jobs. In addition, Novartis confirmed that it is working to develop new therapies for rare diseases, with a particular focus on finding new solutions for the treatment of multiple sclerosis. This is an area in which the company has already shown itself to be a leader, thanks to its basic therapy for multiple sclerosis, which was approved in Switzerland in 2017. Here are some concrete examples of Novartis' actual numbers: - 2022 turnover: 49.1 billion Swiss francs - 2022 adjusted operating profit: 9.5 billion Swiss francs - 2022 research and development investments: 3.5 billion Swiss francs The company also announced that it has reached an agreement with the Swiss federal government for the creation of an investment fund for the research and development of new technologies. This fund, which provides for an investment of 500 million Swiss francs, is expected to be completed by 2028 and is expected to create around 200 new jobs.